Technical Analysis for BCRX - BioCryst Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade D 4.96 1.85% 0.09
BCRX closed up 1.85 percent on Friday, February 16, 2018, on 1.12 times normal volume. It ran into resistance at its 50 day moving average. Its advance stalled at its 200 day moving average, an important long-term support / resistance line. The price action carved out a bearish shooting star candlestick pattern. That may indicate a downside reversal. Look for price to trade beneath the low of the shooting star for confirmation.
4 Watchers
Track This Stock
Watchlist Portfolio

Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Up
See historical BCRX trend table...

Date Alert Name Type % Chg
Feb 16 200 DMA Resistance Bearish 0.00%
Feb 16 50 DMA Resistance Bearish 0.00%
Feb 16 Shooting Star Candlestick Bearish 0.00%
Feb 16 Lizard Bearish Bearish Day Trade Setup 0.00%
Feb 16 Wide Bands Range Expansion 0.00%
Feb 15 Bearish Engulfing Bearish 1.85%
Feb 15 Fell Below 50 DMA Bearish 1.85%
Feb 15 Wide Bands Range Expansion 1.85%
Feb 15 Overbought Stochastic Strength 1.85%
Feb 14 200 DMA Resistance Bearish -2.94%

Older signals for BCRX ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

BioCryst Pharmaceuticals, Inc., a biotechnology company, designs, optimizes, and develops novel drugs that block key enzymes involved in the pathogenesis of diseases. The company integrates the disciplines of biology, crystallography, medicinal chemistry, and computer modeling to discover and develop small molecule pharmaceuticals through the structure-guided drug design process. Its product candidates include peramivir, an intravenous neuraminidase inhibitor, which is approved for seasonal influenza in Japan and Korea, as well as in Phase III clinical trials for acute influenza; ulodesine, an oral purine nucleoside phosphorylase inhibitor, which has completed Phase II clinical trials for the treatment of gout; and forodesine, an oral purine nucleoside phosphorylase inhibitor that is in Phase II clinical trials for oncology. The company's product candidates also comprise BCX4161, a Phase I oral serine protease inhibitor for kallikrein hereditary angioedema; and BCX4430, a preclinical, RNA dependent-RNA polymerase inhibitor for treating Filoviruses. It has collaborative relationships with Mundipharma International Holdings Limited for the development and commercialization of forodesine; and Shionogi & Co., Ltd. and Green Cross Corporation for the development and commercialization of peramivir. Biocryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
Is BCRX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 9.25
52 Week Low 3.95
Average Volume 1,367,234
200-Day Moving Average 5.1428
50-Day Moving Average 5.0724
20-Day Moving Average 4.805
10-Day Moving Average 4.865
Average True Range 0.2944
ADX 26.4
+DI 16.46
-DI 20.34
Chandelier Exit (Long, 3 ATRs ) 4.9168
Chandelier Exit (Short, 3 ATRs ) 5.1332
Upper Bollinger Band 5.3217
Lower Bollinger Band 4.2883
Percent B (%b) 0.65
BandWidth 21.506764
MACD Line -0.0492
MACD Signal Line -0.0918
MACD Histogram 0.0425
Fundamentals Value
Market Cap 398.92 Million
Num Shares 80.4 Million
EPS -0.62
Price-to-Earnings (P/E) Ratio -8.00
Price-to-Sales 11.43
Price-to-Book 13.91
PEG Ratio -0.28
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 5.50
Resistance 3 (R3) 5.53 5.39 5.41
Resistance 2 (R2) 5.39 5.25 5.37 5.38
Resistance 1 (R1) 5.17 5.16 5.28 5.14 5.35
Pivot Point 5.03 5.03 5.08 5.01 5.03
Support 1 (S1) 4.81 4.89 4.92 4.78 4.57
Support 2 (S2) 4.67 4.80 4.65 4.54
Support 3 (S3) 4.45 4.67 4.51
Support 4 (S4) 4.42